AI Tokens
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Cytokinetics Inc., liquidity ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current ratio 9.40 7.45 15.20 8.98 9.36
Quick ratio 9.25 7.28 15.02 8.85 9.05
Cash ratio 9.25 6.56 14.87 8.65 8.95

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The liquidity profile of the organization remains exceptionally strong from 2018 through 2022, characterized by ratios that significantly exceed standard benchmarks. A volatile but high liquidity posture is evident, with a notable peak in 2020 followed by a contraction in 2021 and a subsequent recovery in 2022.

Current Ratio
The current ratio exhibited significant fluctuations, rising from 9.36 in 2018 to a peak of 15.20 in 2020. A sharp contraction to 7.45 occurred in 2021, before returning to 9.40 by the end of 2022. This trajectory indicates an aggressive accumulation of current assets relative to liabilities in 2020, followed by a period of increased capital utilization.
Quick Ratio
The quick ratio closely mirrors the movements of the current ratio, starting at 9.05 in 2018 and peaking at 15.02 in 2020. The minimal variance between the current and quick ratios suggests that the entity holds negligible inventory, as liquidity is not dependent on the sale of physical goods to meet short-term obligations.
Cash Ratio
The cash ratio followed an identical pattern, peaking at 14.87 in 2020 and dipping to 6.56 in 2021. The close alignment between the cash ratio and the quick ratio indicates that the vast majority of liquid assets are held in cash or cash equivalents, providing a high level of solvency and financial flexibility.

The convergence of all three liquidity metrics suggests a financial structure heavily weighted toward cash holdings. While the decline in 2021 represents a relative reduction in liquidity, the ratios maintained in 2022 continue to indicate an over-capitalized position regarding short-term liabilities.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Current Ratio

Cytokinetics Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Current assets 795,186 535,672 474,221 233,752 207,674
Current liabilities 84,617 71,860 31,199 26,023 22,194
Liquidity Ratio
Current ratio1 9.40 7.45 15.20 8.98 9.36
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.96 0.79 — — —
Amgen Inc. 1.41 1.59 — — —
Bristol-Myers Squibb Co. 1.25 1.52 — — —
Danaher Corp. 1.89 1.43 — — —
Eli Lilly & Co. 1.05 1.23 — — —
Gilead Sciences Inc. 1.29 1.27 — — —
Johnson & Johnson 0.99 1.35 — — —
Merck & Co. Inc. 1.47 1.27 — — —
Pfizer Inc. 1.22 1.40 — — —
Regeneron Pharmaceuticals Inc. 5.06 3.56 — — —
Thermo Fisher Scientific Inc. 1.48 1.50 — — —
Vertex Pharmaceuticals Inc. 4.83 4.46 — — —
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.30 1.36 — — —
Current Ratio, Industry
Health Care 1.23 1.31 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 795,186 ÷ 84,617 = 9.40

2 Click competitor name to see calculations.


The liquidity position remains exceptionally strong throughout the period ending December 31, 2022, characterized by current assets that consistently and significantly exceed current liabilities. This indicates a robust capacity to meet short-term financial obligations with a substantial margin of safety.

Current Assets Growth
A sustained upward trend in current assets is observed, increasing from US$ 207.7 million in 2018 to US$ 795.2 million in 2022. The most significant expansion occurred between 2019 and 2020, where assets more than doubled, followed by further substantial growth in 2022.
Current Liabilities Trend
Current liabilities grew from US$ 22.2 million in 2018 to US$ 84.6 million in 2022. While the growth was modest between 2018 and 2020, a more pronounced increase occurred in 2021 and 2022. Despite this rise, liabilities have remained a small fraction of total current assets.
Current Ratio Analysis
The current ratio exhibited volatility, peaking at 15.20 in 2020 before declining to a period low of 7.45 in 2021, and subsequently recovering to 9.40 in 2022. Although the ratio fluctuated, it remained consistently high, suggesting an extremely liquid balance sheet that far exceeds typical industry requirements for short-term solvency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Quick Ratio

Cytokinetics Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 65,582 112,666 82,985 36,433 42,256
Short-term investments 716,995 358,972 381,075 188,679 156,475
Accounts receivable 147 51,819 4,420 5,163 2,231
Total quick assets 782,724 523,457 468,480 230,275 200,962
 
Current liabilities 84,617 71,860 31,199 26,023 22,194
Liquidity Ratio
Quick ratio1 9.25 7.28 15.02 8.85 9.05
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.69 0.56 — — —
Amgen Inc. 0.95 1.06 — — —
Bristol-Myers Squibb Co. 0.87 1.20 — — —
Danaher Corp. 1.30 0.89 — — —
Eli Lilly & Co. 0.62 0.79 — — —
Gilead Sciences Inc. 0.99 0.95 — — —
Johnson & Johnson 0.71 1.04 — — —
Merck & Co. Inc. 0.93 0.73 — — —
Pfizer Inc. 0.80 1.00 — — —
Regeneron Pharmaceuticals Inc. 4.16 2.98 — — —
Thermo Fisher Scientific Inc. 1.06 1.00 — — —
Vertex Pharmaceuticals Inc. 4.46 4.04 — — —
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.91 0.98 — — —
Quick Ratio, Industry
Health Care 0.93 1.00 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 782,724 ÷ 84,617 = 9.25

2 Click competitor name to see calculations.


The liquidity position of the organization exhibits a strong upward trajectory in terms of asset accumulation, maintaining a highly conservative buffer against short-term obligations over the five-year period ending December 31, 2022.

Trend in Quick Assets
Total quick assets experienced consistent growth, rising from US$ 200,962 thousand in 2018 to US$ 782,724 thousand in 2022. Notable surges in liquidity are observed in 2020 and 2022, indicating significant increases in the most liquid components of the balance sheet.
Current Liabilities Progression
Current liabilities increased from US$ 22,194 thousand in 2018 to US$ 84,617 thousand in 2022. A marked acceleration in obligations occurred between 2020 and 2021, where liabilities more than doubled, although the total amount remains small relative to the available quick assets.
Quick Ratio Analysis
The quick ratio remained exceptionally high throughout the period, significantly exceeding the standard liquidity benchmark of 1.0. The ratio peaked at 15.02 in 2020 before declining to a period low of 7.28 in 2021, a change driven by the sharp increase in current liabilities during that year. By December 31, 2022, the ratio recovered to 9.25, reflecting a continued capacity to cover short-term debts multiple times over using only quick assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Cash Ratio

Cytokinetics Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 65,582 112,666 82,985 36,433 42,256
Short-term investments 716,995 358,972 381,075 188,679 156,475
Total cash assets 782,577 471,638 464,060 225,112 198,731
 
Current liabilities 84,617 71,860 31,199 26,023 22,194
Liquidity Ratio
Cash ratio1 9.25 6.56 14.87 8.65 8.95
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.31 0.28 — — —
Amgen Inc. 0.59 0.66 — — —
Bristol-Myers Squibb Co. 0.42 0.78 — — —
Danaher Corp. 0.71 0.32 — — —
Eli Lilly & Co. 0.12 0.25 — — —
Gilead Sciences Inc. 0.57 0.56 — — —
Johnson & Johnson 0.42 0.70 — — —
Merck & Co. Inc. 0.54 0.34 — — —
Pfizer Inc. 0.54 0.73 — — —
Regeneron Pharmaceuticals Inc. 2.46 1.45 — — —
Thermo Fisher Scientific Inc. 0.50 0.33 — — —
Vertex Pharmaceuticals Inc. 3.93 3.51 — — —
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.52 0.58 — — —
Cash Ratio, Industry
Health Care 0.54 0.60 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 782,577 ÷ 84,617 = 9.25

2 Click competitor name to see calculations.


An analysis of the liquidity position from 2018 to 2022 reveals a company with an exceptionally strong cash reserve and a high capacity to meet short-term obligations. The overall trend is characterized by aggressive accumulation of cash assets, which has consistently outpaced the growth of current liabilities, maintaining a substantial liquidity cushion throughout the period.

Total Cash Assets Growth
A significant upward trajectory in cash holdings is observed, with assets increasing from 198,731 thousand US dollars in 2018 to 782,577 thousand US dollars by 2022. Notable surges occurred in 2020 and 2022, indicating periods of substantial capital infusion or strategic cash accumulation.
Current Liabilities Expansion
Current liabilities remained relatively stable between 2018 and 2020, ranging from 22,194 thousand to 31,199 thousand US dollars. However, a marked increase occurred in 2021 and 2022, with liabilities rising to 84,617 thousand US dollars, suggesting an increase in short-term operational costs or financing obligations.
Cash Ratio Volatility and Interpretation
The cash ratio exhibits considerable fluctuation, peaking at 14.87 in 2020 before declining to a period low of 6.56 in 2021 and recovering to 9.25 in 2022. The 2020 peak was driven by a surge in cash assets that far exceeded the growth in liabilities. The 2021 decline was primarily a result of current liabilities more than doubling while cash assets remained nearly flat. By 2022, the ratio improved again as cash growth resumed a more aggressive pace than liability growth.

Despite the volatility in the cash ratio, the values remain well above the standard benchmark of 1.0, indicating that the entity possesses more than enough liquid assets to cover its current liabilities multiple times over. This suggests a low risk of short-term insolvency and significant financial flexibility for future operations or investments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?